GUIDED THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
GUIDED THERAPEUTICS, INC. (GTHP) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$51.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- GUIDED THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $306.00K.
- GUIDED THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$273.00K.
- GUIDED THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$146.00K.
- GUIDED THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$476.00K, a 680.49% decline year-over-year.
- GUIDED THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$325.00K.
- GUIDED THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$203.00K.
- GUIDED THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$1.72M, a 203.11% decline from fiscal 2022.
- GUIDED THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $1.67M, a 262.26% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$51.00K 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $306.00K 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | -$325.00K 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$301.00K 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | -$203.00K 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | -$273.00K 10-Q · filed 2026-05-15 | ||||
| 2024-12-31 | -$203.00K 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | -$397.00K 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | -$316.00K 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | -$146.00K 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | -$1.72M 10-K · filed 2024-03-28 | ||||
| 2023-09-30 | -$1.58M 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | -$955.00K 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | -$476.00K 10-Q · filed 2024-05-14 | ||||
| 2022-12-31 | $1.67M 10-K · filed 2024-03-28 | $1.67M 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $2.05M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | -$197.00K 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | $82.00K 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | $461.00K 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $359.00K 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | $740.00K 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $1.06M 10-Q · filed 2022-05-16 |